Avesthagen completes AVDESP clinical batch manufacturing in Malaysia
The drug substance batches for AVDESP, which have been developed by Malaysia’s biopharma CMO – Inno Biologics, will be used to conduct clinical trials after formulation of the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.